Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes

NCT00252772 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00252772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00252772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2004
Completion date
November 30, 2006
Enrollment
80
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes